首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1482460

微量殘存疾病檢測市場：按技術、按應用、按最終用戶、按地區

Minimal Residual Disease Testing Market, By Technology (Flow Cytometry, Polymerase chain reaction, and Next generation sequencing), By Application, By End User, By Geography

出版日期: 2024年04月11日 | 出版商:

Coherent Market Insights | 英文 173 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

微量殘存疾病檢測市場預計到2024年將達到23.1億美元，預計到2031年將達到49.7億美元，2024年至2031年的年複合成長率為11.6%。

報告範圍		報告詳情
基準年	2023年	2024年市場規模	23.1億美元
實際資料	2019年至2023年	預測期	從2024年到2031年
預測2024-2031年年複合成長率：	11.60%	2031年的預測值	49.7億美元

圖：2024年依地區分類的微量殘存疾病檢測市場佔有率（%）

微量殘存疾病（MRD）檢測可檢測初始治療後可能殘留在體內的少量癌細胞。 MRD 檢測是血液學家和腫瘤學家監測治療效果和預測患者結果的重要工具。 MRD 檢測使醫生能夠比其他方法更早識別疾病復發風險較高的患者。這將有助於確定是否需要額外的治療或更密切的監測。多種技術已用於高靈敏度檢測 MRD，包括多參數流式細胞技術、對偶基因特異性特異性寡核苷酸定量 PCR 和次世代定序。隨著MRD檢測在各類血癌的廣泛應用和技術的改進，預計未來幾年市場將顯著成長。

市場動態：

全球微量殘存疾病檢測市場的推動因素包括血癌盛行率上升、治療監測中 MRD 檢測的日益採用以及醫生意識的提高。然而，缺乏熟練的專業人員、檢測方法的高指數化以及某些地區的償付問題限制市場的成長。該公司推出各種具有更高靈敏度和自動化平台的新產品，這是一個重大商機。例如，個人化治療和液態切片技術都是新領域。公司和研究機構之間的合作研究也支持市場向新地區的擴張。儘管 COVID-19 大流行對醫療保健資源的影響是一個挑戰，遠端醫療和家庭樣本採集支持當前情況下 MRD 監測的連續性。

本研究的主要特點

本報告對全球微量殘存疾病檢測市場進行了詳細分析，並列出了以2023年為基準年的預測期（2024-2031年）的市場規模和年複合成長率（CAGR%）。
它說明了各個細分市場的潛在收益成長機會，並為該市場提供了一系列有吸引力的投資提案。
提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的主要考察。
本報告根據公司亮點、產品系列、主要亮點、財務表現和策略等參數，介紹了全球微量殘存疾病檢測市場的主要企業。
本報告的見解使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球微量殘存疾病檢測市場迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過用於分析全球微量殘存疾病檢測市場的各種策略矩陣，將有助於相關人員做出決策。

公司簡介
- Bio-Rad Laboratories, Inc.
- F. Hoffmann-La Roche Ltd
- Guardant Health, Inc.
- Adaptive Biotechnologies
- Invitae Corporation
- ASURAGEN, INC.
- Invivoscribe, Inc.
- Laboratory Corporation of America Holdings
- Natera, Inc.
- Sysmex Inostics, Inc.
- Amgen Inc.
- FOUNDATION MEDICINE, INC.
- Sebia
- Myriad Genetics, Inc.

第10章分析師的觀點

分析師觀點
Coherent Opportunity Map

第11章參考文獻與調查方法

參考
調查方法

簡介目錄

Product Code: CMI6888

The minimal residual disease testing market is estimated to be valued at USD 2.31 Bn in 2024 and is expected to reach USD 4.97 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 11.6% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 2.31 Bn
Historical Data for:	2019 To 2023	Forecast Period:	2024 To 2031
Forecast Period 2024 to 2031 CAGR:	11.60%	2031 Value Projection:	US$ 4.97 Bn

Figure. Minimal Residual Disease Testing Market Share (%), By Region 2024

Minimal Residual Disease Testing Market - IMG1

Minimal Residual Disease (MRD) testing involves detecting tiny amounts of residual cancer cells that may remain in the body after initial treatment. It is an important tool for both hematologists and oncologists to monitor treatment response and predict outcomes for patients. MRD testing allows physicians to identify those who may be at higher risk of disease relapse earlier than other methods. This helps determine if additional therapies or closer monitoring is needed. Several technologies such as multiparameter flow cytometry, allele-specific oligonucleotide quantitative PCR, and next generation sequencing are used to detect MRD with high sensitivity. With growing applications of MRD testing across different types of blood cancers and improving technologies, the market is expected to witness significant growth in the coming years.

Market Dynamics:

The global minimal residual disease testing market is driven by rising incidence of hematological cancers, increasing adoption of MRD testing in treatment monitoring, and growing awareness among physicians. However, lack of skilled professionals, high index of testing methods, and reimbursement issues in some regions are restraining the market growth. Various new product launches by players with improved sensitivity and automated platforms present key opportunities. For instance, personalized therapy and liquid biopsy techniques are emerging areas. Collaborations between companies and research institutes are also supporting market expansion into new geographies. The effects of the COVID-19 pandemic on healthcare resources is a challenge, though telemedicine and home-based sample collection aid continuity of MRD monitoring in current scenario.

Key Features of the Study:

This report provides an in-depth analysis of the global minimal residual disease testing market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global minimal residual disease testing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study includes Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Guardant Health, Inc., Adaptive Biotechnologies, Invitae Corporation, ASURAGEN, INC., Invivoscribe, Inc., Laboratory Corporation of America Holdings, Natera, Inc., Sysmex Inostics, Inc., Amgen Inc., FOUNDATION MEDICINE, INC., Sebia, and Myriad Genetics, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global minimal residual disease testing market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global minimal residual disease testing market

Detailed Segmentation-

Technology:
- Flow Cytometry
- Polymerase chain reaction (PCR)
- Next generation sequencing
Application:
- Lymphoma
- Solid Tumors
- Others
End User:
- Hospitals
- Clinics
- Research Laboratories
- Others
Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Bio-Rad Laboratories, Inc.
- Hoffmann-La Roche Ltd
- Guardant Health, Inc.
- Adaptive Biotechnologies
- Invitae Corporation
- ASURAGEN, INC.
- Invivoscribe, Inc.
- Laboratory Corporation of America Holdings
- Natera, Inc.
- Sysmex Inostics, Inc.
- Amgen Inc.
- FOUNDATION MEDICINE, INC.
- Sebia
- Myriad Genetics, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Technology
- Market Snapshot, By Application
- Market Snapshot, By End User
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Epidemiology
Recent Developments
Acquisitions and Partnerships Scenario
Funding and Investments
PEST Analysis
Porter's Analysis

4. Global Minimal Residual Disease Testing Market- Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the Market

5. Global Minimal Residual Disease Testing Market, By Technology, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Flow Cytometry
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Polymerase chain reaction (PCR)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Minimal Residual Disease Testing Market, By Application, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Lymphoma
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Solid Tumors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Minimal Residual Disease Testing Market, By End User, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospitals
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Clinics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Research Laboratories
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Minimal Residual Disease Testing Market, By Region, 2019 - 2031, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Regions, 2020-2031
- Regional Trends
  - North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.S.
  - Canada
  - Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
  - Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
  - Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
  - Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - GCC
  - Israel
  - Rest of Middle East
  - Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profiles
- Bio-Rad Laboratories, Inc.*
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- F. Hoffmann-La Roche Ltd
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Guardant Health, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Adaptive Biotechnologies
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Invitae Corporation
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- ASURAGEN, INC.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Invivoscribe, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Laboratory Corporation of America Holdings
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Natera, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Sysmex Inostics, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Amgen Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- FOUNDATION MEDICINE, INC.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Sebia
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Myriad Genetics, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies